Shire Kills Momenta Biosim Deal

Source: BBC News

Sep 28, 2016

Shire has terminated its collaboration with Momenta Pharma to develop and commercialize a Humira biosimilar.

At the start of 2016, UK-based Shire struck a $32 bn deal to acquire U.S. rival, Baxalta. The collaboration between Baxalta and Momenta to develop and commercialize M923, a proposed Humira biosimilar, met a primary endpoint in December 2015.  

As part of the Shire-Baxalta deal, Shire sought to achieve double-digit revenue growth with total revenue to exceed $20 billion by 2020. According to Momenta, Shire terminated the partnership “based on a comprehensive portfolio assessment.” 

Shire will now begin to work to transfer all ongoing clinical, regulatory and commercialization activities for M923 to Momenta.

Read the BBC news coverage


Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments